Comparing a new digital PCR test for hepatitis B virus
Part of Digestive system, Infections clinical trials.
This study compares a new, highly sensitive digital PCR test to the standard test for measuring hepatitis B virus (HBV) DNA in the blood. It uses leftover blood samples from people with chronic hepatitis B to see if the new test is just as accurate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic hepatitis B (a long-term liver infection).
- You are 18 years old or older.
- You have a leftover blood sample from a previous HBV DNA test (taken within the last 6 months) that is still usable.
- You do not have other liver infections like hepatitis C, hepatitis D, or HIV.
- Your leftover blood sample is at least 1 mL (about a fifth of a teaspoon) and hasn't been thawed and refrozen more than 2 times.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, GST-HG131, for people with chronic hepatitis B who are already on stable treatment. It aims to see if the drug is safe and reduces the virus further.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This trial tests a new drug called GST-HG141 for people with chronic hepatitis B whose virus is still active despite taking standard antiviral pills. It aims to see if the new drug can better control the virus.
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.